One intravitreal injection of 4D-150 helped reduce the mean annualized anti-VEGF injection rate in patients with wet age-related macular degeneration, according to a study presented at the American Society of Retina Specialists meeting.
“The PRISM phase 2 data at 24 weeks across a broad patient population with varying severity of disease, along with long-term data collected through up to 2.5 years, confirms 4D-150’s potential to significantly reduce the treatment burden and maintain vision through a safe, single intravitreal injection,” David Kirn, MD, co-founder and CEO of